AQUEOUS PHARMACEUTICAL FORMULATIONS

Provided are an aqueous pharmaceutical formulation comprising an antibody specific to the receptor of interleukin (IL) -6 (for example, Tocilizumab) and an effective amount of histidine for stabilizing the antibody. Said histidine is present in the aqueous pharmaceutical formulation at a concentrati...

Full description

Saved in:
Bibliographic Details
Main Authors LIU, Jiung-Liang, YANG, Jheng-Gang, CHANG, Wen-Cheng
Format Patent
LanguageEnglish
French
Published 07.05.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided are an aqueous pharmaceutical formulation comprising an antibody specific to the receptor of interleukin (IL) -6 (for example, Tocilizumab) and an effective amount of histidine for stabilizing the antibody. Said histidine is present in the aqueous pharmaceutical formulation at a concentration of 50 mM to 200 mM so as to achieve the stabilizing effect. L'invention concerne une formulation pharmaceutique aqueuse comprenant un anticorps spécifique au récepteur de l'interleukine (IL)-6 (par exemple, Tocilizumab) et une quantité efficace d'histidine pour stabiliser l'anticorps. Ladite histidine est présente dans la formulation pharmaceutique aqueuse à une concentration de 50 mM à 200 mM de manière à obtenir l'effet stabilisant.
Bibliography:Application Number: WO2019CN113112